Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Abstract
Mouse ovarian surface epithelial cells (MOSEC) were obtained from virgin, mature mice by mild trypsinization and were repeatedly passaged in vitro. Early passage cells (<20 passages) exhibited a cobblestone morphology and contact inhibition of growth. After approximately 20 passages in vitro, cobblestone morphology and contact inhibition of growth was lost. Tumor forming potential was determined by s.c. and i.p. injection of early and late passage cells into athymic and syngeneic C57BL6 mice. Subcutaneous tumors formed in approximately 4 months and were present only at the injection site. Intraperitoneal injection of late passage MOSEC into athymic and syngeneic mice resulted in growth of tumor implants throughout the abdominal cavity, and production of hemorrhagic ascitic fluid. Early passage MOSEC did not form tumors in vivo. Histopathologic analysis of tumors revealed a highly malignant neoplasm containing both carcinomatous and sarcomatous components. Late passage MOSEC expressed cytokeratin and did not produce ovarian steroids in response to gonadotropin stimulation in vitro. Ten clonal lines were established from late passage MOSEC. Each clone formed multiple peritoneal tumors and ascitic fluid after i.p. injection into C57BL6 mice. Three cell lines examined cytogenetically were polyploid with near-tetraploid modal chromosome numbers. Common clonal chromosome gains and losses included +5, +15, +19 and -X, -3, -4. One cell line had a clonal translocation between chromosomes 15 and 18 and another had a small marker chromosome; common structural abnormalities were not observed. These data describe the development of a mouse model for the study of events related to ovarian cancer in humans. The ability of the MOSEC to form extensive tumors within the peritoneal cavity, similar to those seen in women with Stage III and IV cancer, and the ability of the MOSEC to produce tumors in mice with intact immune systems, makes this model unique for investigations of molecular and immune interactions in ovarian cancer development.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The murine ID8 ovarian cancer cell line has been used for a number of syngeneic mouse models, achieving primary ovarian tumors and ascites within 90 days.
“The murine ID8 ovarian cancer cell line (C57Bl/6 background) (Roby et al., 2000), has been used for a number of syngeneic mouse models, achieving primary ovarian tumors and ascites within 90 days (Greenaway et al., 2008).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Roby et al., 2000
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 30 · Cited by 593
Research works printed but not linked: 1
- Miller,D., Spirtos,N., Ballon,S., Cox,R., Soriero,O. and Teng,N. (1992) Critical reassessment of second-look exploratory laparotomy for epithelial IRL Press, New York.
- Authors
- Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F.
- Affiliations
- University of Kansas Medical Center (US)
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-01
- Volume
- 21
- Issue
- 4
- Pages
- 585-591
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2171249989
- Cited by
- 593
- References
- 30
- Citations by year
- 2026: 14 · 2025: 31 · 2024: 31 · 2023: 36 · 2022: 32 · 2021: 42 · 2020: 31 · 2019: 34 · 2018: 31 · 2017: 23 · 2016: 29 · 2015: 25 · 2014: 18 · 2013: 31 · 2012: 28
- FWCI
- 7.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Carcinogenesis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca050616-12)
- National Cancer Institute (R01 CA50616)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Biology and Fertility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- ovarian cancer, syngeneic mouse model, ovarian surface epithelial cells, peritoneal carcinomatosis, ascites, clonal chromosomal abnormalities, polyploidy, cytokeratin expression, ovarian steroidogenesis, tumor immunology
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Cells, Cultured, Chromosome Aberrations, Disease Models, Animal, Epithelial Cells, Female, Mice, Inbred C57BL, Ovarian Neoplasms, Ovary, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
